New Strategies in Cholesterol Management: Stopping Production Instead of Removal

If previous recommendations for high cholesterol have never quite worked for you, there’s a growing field of research suggesting a radical shift in approach: rather than clearing cholesterol from the bloodstream, why not just stop your body from making it in the first place?

This perspective is especially relevant for individuals with familial hypercholesterolemia (FH), a genetic disorder impacting millions and often overlooked. FH prevents the effective clearing of LDL cholesterol, which is notorious for clogging arteries.

A Genetic Condition Affecting Cholesterol Levels

In healthy individuals, LDL receptors in the liver extract cholesterol from the bloodstream, helping to keep levels stable. In those with FH, mutations disrupt the function of these receptors, leading to elevated cholesterol levels over time—often with no overt symptoms until a significant health event occurs, such as a heart attack.

This genetic disorder is surprisingly common, with approximately 1 in 200 adults showing signs, many of whom are unaware of their condition. For these individuals, standard treatments like statins may not suffice.

Why Statins May Fall Short

Statins have long been the first choice for managing cholesterol, effectively enhancing LDL receptor function. However, for those with severe FH characteristics, especially when defective genes are inherited from both parents, the limitations of statins become glaringly apparent.

This realization has spurred researchers to consider a different angle: Instead of facilitating the body's ability to clear cholesterol, what if we concentrated on reducing cholesterol production at its source?

Targeting Apolipoprotein B (ApoB)

Researchers at the Medical University of South Carolina (MUSC) have recently shifted focus to ApoB, a protein critical to the formation of LDL particles. Think of ApoB as the framework necessary for LDL particle assembly; without it, cholesterol transport cannot even begin.

By aiming to decrease ApoB levels, the researchers hope to limit the release of cholesterol from the liver entirely—a method that circumvents issues associated with impaired LDL receptors.

The research, published in Communications Biology, employed induced pluripotent stem cells (iPSCs) to recreate liver-like cells for testing. This model provides a more accurate view of human liver function than standard animal studies.

Research Findings and Implications

The research team screened around 130,000 compounds, identifying several that significantly reduced ApoB levels, cholesterol, and triglycerides. Stephen Duncan, D.Phil., who led the study, emphasized the novel aspect of screening for effective drugs without initially understanding their exact mechanisms, noting its potential for advancing pharmacology.

While initial tests in standard mice yielded minimal results—attributable to the species' differing liver responses—the compounds showed promising results in specially engineered 'Avatar' mice carrying human liver cells. This created a more reliable model for testing drug effects.

Promising Follow-Up Research

Continued research into the lead compound, DL-1, was documented in a recent study where RNA sequencing revealed that it affected a limited number of genes, avoiding major disruptions in overall liver function. Most intriguingly, it seemed to modulate the processing and release of ApoB, offering insights into a less invasive mechanism for addressing cholesterol production.

Next Steps in Treatment Development

While these compounds aren’t available for treatment yet, their development marks a significant shift in how we might approach high cholesterol management in the future. More testing is required to fully understand the compounds' molecular actions and long-term safety, along with their compatibility with existing therapies.

Nonetheless, the implications of this research offer real hope. Duncan highlights the efficiency of discovering drugs through human models, positing that this method could enhance the pace of finding effective treatments that genuinely work for patients, as opposed to animal-centric studies.

The Path Ahead

For many, the conventional strategy—lifestyle adjustments, the use of statins where necessary, and regular medical consultations—remains effective. However, for those grappling with familial hypercholesterolemia, particularly in severe instances where traditional treatments fall short, this research heralds a new and potentially more effective strategy, targeting cholesterol production at the root rather than simply addressing the aftermath.